NCT03819153), secondary analyses of GLP-1RA CVOTs indicate that liraglutide [17], semaglutide [18], dulaglutide [25] and efpeglenatide [20] may reduce the relative risk of a composite kidney outcome, comprising new-onset macroalbuminuria, worsening kidney function, end-stage renal disease and renal death, by 1536%
Hiromura M, Mori Y, Kohashi K, et al
They are commonly prescribed for neuropathies, vitamin deficiencies, and general wellness
Where in the fridge you store it also matters
Federico Cerrone, MD, sleep specialist and medical director of Atlantic Health System Sleep Centers, cares for patients with obstructive sleep apnea
The best protocol is one that matches your goals, your biology, your tolerance profile, and your providers clinical assessment